30th May 2014 05:48
LONDON (Alliance News) - GlaxoSmithKline PLC has invited private equity firms to bid for some of its older drugs in the latest step by Chief Executive Andrew Witty to reshape the UK?s biggest drugmaker, the Financial Times reports Friday, citing people familiar with the situation.
Private equity companies including Advent International, Blackstone and KKR are among those to have been alerted to the opportunity, The FT quoted the people as saying.
http://www.ft.com/cms/s/0/2f795102-e750-11e3-8b4e-00144feabdc0.html?ftcamp=crm/email/2014530/nbe/UKBusiness/product&siteedition=uk#axzz3354lAN00
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline